Plant-based Vaccines Market 2020: New Opportunities & SWOT Analysis by Top Players Medicago, Inc., iBio, Inc., and Icon Genetics- GmbH

Existing key players and new entrants in the plant-based vaccines market are focused on extensive clinical trial studies to develop plant-based vaccines for numerous therapeutic applications.

For instance, Medicago Inc., a clinical-stage biotechnology company, which uses plant-based technologies to develop and produce novel vaccine and antibodies, is cultivating several tobacco plants (Nicotiana tabacum) at Durham's Research Triangle Park, North America, which will be used in testing and production of the flu vaccine. In March 2018, Medicago conducted phase III clinical trials to develop flu vaccine, which is expected to be launched in the market by 2020-2021 influenza season.

Request Sample Copy of This Report: https://www.coherentmarketinsights.com/insight/request-sample/2004

Furthermore, researchers require five to six weeks for production of plant-based vaccine, as compared to five to six month period to prepare the vaccine in chicken eggs, which is currently practiced by vaccine manufacturers.

Besides cost-efficiency, plant-based vaccines offer several benefits over conventional egg-based vaccine production, in terms of production time and enhancing immune system of the patient. For instance, Medicago's Quadrivalent Influenza Vaccine (QIV) is produced using novel Virus-Like Particle (VLP) technology, which offers new approach in vaccine development and production. In VLP technology, the vaccine mimics the native structure of viruses, allowing them to easily get penetrated into patient’s immune system. Moreover, the QIV vaccine lacks core genetic material, rendering them to become non-infectious and unable to replicate. This makes plant-based vaccine safe and effective in inducing immune response of patient similar to natural infection without infecting the patient.

Plant-based vaccine production offers better alternative over egg-based and cell-based vaccine production systems, by reducing lead time and increasing reliability and versatility. Furthermore, plant-based vaccine offers greater antigen specificity in disease treatment. Plant-based vaccine production enables manufacturers to create vaccine, which precisely matches the specific strain of influenza virus in patient’s circulation, as in case of flu infection, influenza virus mutates is constantly. For instance, according to Phase III clinical data study published by Medicago, in September 2017, Medicago's VLP vaccine during the phase II clinical trial stage showed higher antibody and cell-mediated immunity (CMI) responses over comparator conventional vaccine.

However, several challenges in manufacturing of plant-based vaccines is expected to restrain growth of the market. Plant-based vaccine production is a new technology and involves complex manufacturing and regulatory process. In egg-based production, whole flu viruses are injected into eggs, which then replicate and form the basis for the vaccine.

Get Up to 30% Discount on the first purchase of this report @ https://www.coherentmarketinsights.com/insight/request-discount/2004

In plant-based vaccine production method, manufacturers use only specific gene, which codes for protein called hemagglutinin, which is responsible for triggering immune system and encodes it into the tobacco plant leaves. In this context, companies need to pursue the U.S. Food and Drug Administration (FDA) approval to state that not only plant-based vaccine is safe and effective, but also the hemagglutinin or other proteins, which can be extracted from the plant leaves are according to the mentioned standard and that the manufacturing process yields a uniform and reliable product.

Although various plant-based vaccines have been developed in various transgenic plants such as insulin in transgenic safflower, taliglucerase alfa in transgenic carrot, avian influenza vaccine in transgenic tobacco, and Ebola vaccine in transgenic tobacco, no plant-derived vaccine is yet approved for human consumption.

Moreover, some of the challenges to develop effective vaccines from downstream processing to the implementation of the vaccines include, selection of antigen & plant expression host, uniformity of dosage, and manufacturing of plant vaccines according to Good Manufacturing Practice (GMP) procedures.

Apply Promo Code “STAYHOME” and Get Up to 30% Discount

If you purchase the report this year:

Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/2004

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

Primary Research (Trade Surveys and Experts Interviews)
Desk Research
Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

Contact Us

Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.